Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275111 | 1.00 | HCRTR1 (0.47) | HCRTR1HCRTR2TP53MDM2EHMT2 | |
| SCHEMBL30829326 | 1.00 | HCRTR1 (0.47) | HCRTR1HCRTR2TP53MDM2EHMT2 | |
| SCHEMBL22443601 | 0.91 | HCRTR1 (0.52) | HCRTR1HCRTR2EHMT2P2RX7CYP3A4 | |
| SCHEMBL22443602 | 0.91 | HCRTR1 (0.52) | HCRTR1HCRTR2EHMT2P2RX7CYP3A4 | |
| SCHEMBL20193827 | 0.88 | HCRTR1 (0.46) | HCRTR1HCRTR2TP53MDM2EHMT2 | |
| SCHEMBL6703838 | 0.85 | TP53 (0.46) | HCRTR1HCRTR2TP53MDM2EHMT2 | |
| SCHEMBL16057864 | 0.85 | ENPP2 (0.43) | HCRTR1HCRTR2P2RX7TSHR | |
| SCHEMBL11065983 | 0.85 | EHMT2 (0.49) | EHMT2CYP3A4TSHRCYP2C19 | |
| SCHEMBL27278853 | 0.85 | EHMT2 (0.49) | EHMT2CYP3A4TSHRCYP2C19 | |
| SCHEMBL31706028 | 0.84 | ITGB1 (0.47) | HCRTR1HCRTR2TP53MDM2EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3919056-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2970308-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| CN-111454200-A | Compounds and their use for modulating hemoglobin | 全球血液疗法股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| CN-105051044-A | Compounds and their use for modulating hemoglobin | GLOBAL BLOOD THERAPEUTICS INC | 2015-11-11 | — | — | CN | disclosed |
| EP-0934305-A4 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6211184-B1 | TETRAHYDRO-PYRAZINE OR PYRIMIDINE DERIVATIVES; VITRONECTIN RECEPTOR ANTAGONIST; OSTEOPOROSIS; ANTIINFLAMMATORY, ANTITUMOR AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS | MERCK & CO., INC. | 2001-04-03 | — | — | US | disclosed |
| US-5981546-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0934305-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998008840-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0381959-B1 | Cyclohexaneacetamide derivatives | HOFFMANN LA ROCHE (CH) | 1995-05-03 | — | — | EP | disclosed |
| US-5015653-A | Posess Cognitive Enhancement And Antiamnestic Activity | HOFFMANN-LA ROCHE INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0381959-A1 | Cyclohexaneacetamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | HCRTR1 4333/4885HCRTR2 4571/4885TP53 2488/4885 |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | HCRTR1 4333/4885HCRTR2 4571/4885TP53 2488/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | HCRTR1 4333/4885HCRTR2 4571/4885TP53 2488/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | HCRTR1 4333/4885HCRTR2 4571/4885TP53 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.